专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110318348A1 INDUCTION OF MUCOSAL IMMUNE RESPONSES BY MUCOSAL DELIVERY PENTABODY COMPLEX (MDPC) 审中-公开
标题翻译：通过粘膜递送复合物（MDPC）诱导粘膜免疫应答
公开(公告)号：US20110318348A1
公开(公告)日：2011-12-29
申请号：US13124062
申请日：2009-10-13
申请人： Jianbing Zhang , Matthew J. Henry , Wangxue Chen , Steven R. Webb
发明人： Jianbing Zhang , Matthew J. Henry , Wangxue Chen , Steven R. Webb
IPC分类号： A61K39/395 , A61P31/00 , A61P37/08 , A61P37/04
CPC分类号： A61K39/395 , A61K2039/541 , A61K2039/6037 , A61K2039/6056 , A61K2039/645 , C07K16/18 , C07K2317/565 , C07K2317/569 , C07K2317/92
摘要： The subject invention provides, for example, a novel approach to specifically induce intranasal and/or oral mucosal as well as humoral antibody response by administrating a mucosal delivery pentabody complex (MDPC). The MDPC is a complex formed by mixing a target antigen and a mucosal delivery pentabody (MDP) that has a strong affinity to the target antigen. The MDP is a fusion protein of a single domain antibody (sdAb; which binds to the target antigen specifically) to a pentamerization domain (which can include the B-subunit of an AB5 toxin family, including the B subunit of cholera toxin (CT) or heat-labile toxin (LT)). The pentamerization domain can self-assemble into a pentamer, through which a pentameric single domain antibody, or a pentabody, is formed.
摘要翻译：本发明提供了例如通过施用粘膜递送五抗体复合物（MDPC）来特异性诱导鼻内和/或口腔粘膜以及体液抗体应答的新方法。 MDPC是通过混合目标抗原和对靶抗原具有强亲和力的粘膜递送五抗体（MDP）形成的复合物。 MDP是单结构域抗体（sdAb，其特异性结合靶抗原）与五聚体结构域（其可以包括AB5毒素家族的B亚基，包括霍乱毒素（CT）的B亚基）的融合蛋白，或热不稳定毒素（LT））。五聚体结构域可以自组装成五聚体，五聚体单结构域抗体或五肽形成。

2. 发明授权

US09327022B2 BSA-specific antibodies 有权
标题翻译： BSA特异性抗体
公开(公告)号：US09327022B2
公开(公告)日：2016-05-03
申请号：US13124268
申请日：2009-10-14
申请人： Jianbing Zhang , Wangxue Chen , C. Roger MacKenzie , Mehdi Arbabi , Shenghua Li
发明人： Jianbing Zhang , Wangxue Chen , C. Roger MacKenzie , Mehdi Arbabi , Shenghua Li
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00 , C12P21/08 , C07K16/18
CPC分类号： A61K39/395 , A61K2039/541 , A61K2039/6037 , A61K2039/6056 , A61K2039/645 , C07K16/18 , C07K2317/565 , C07K2317/569 , C07K2317/92
摘要： The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.
摘要翻译：本发明涉及血清白蛋白特异性抗体。更具体地，本发明涉及与各种亲和力的各种物种的血清白蛋白结合的骆驼单结构域抗体和五糖多肽。

3. 发明申请

US20110282036A1 BSA-SPECIFIC ANTIBODIES 有权
标题翻译： BSA特异性抗体
公开(公告)号：US20110282036A1
公开(公告)日：2011-11-17
申请号：US13124268
申请日：2009-10-14
申请人： Jianbing Zhang , Wangxue Chen , C. Roger Mackenzie , Mehdi Arbabi , Shenghua Li
发明人： Jianbing Zhang , Wangxue Chen , C. Roger Mackenzie , Mehdi Arbabi , Shenghua Li
IPC分类号： C07K16/18 , C07H21/04 , C12N15/63
CPC分类号： A61K39/395 , A61K2039/541 , A61K2039/6037 , A61K2039/6056 , A61K2039/645 , C07K16/18 , C07K2317/565 , C07K2317/569 , C07K2317/92
摘要： The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.
摘要翻译：本发明涉及血清白蛋白特异性抗体。更具体地，本发明涉及与各种亲和力的各种物种的血清白蛋白结合的骆驼单结构域抗体和五糖多肽。

4. 发明申请

US20110002854A1 Use of Francisella Tularensis For Prevention and Treatment of Allergic Airway Disorders 有权
标题翻译：使用弗朗西斯杜拉氏菌素预防和治疗过敏性气道疾病
公开(公告)号：US20110002854A1
公开(公告)日：2011-01-06
申请号：US12529678
申请日：2008-03-20
申请人： Wangxue Chen , Girishchandra Babubhai Patel
发明人： Wangxue Chen , Girishchandra Babubhai Patel
IPC分类号： A61K9/12 , A61K35/74 , A61P11/06 , A61K38/00
CPC分类号： A61K39/0208 , A61K9/0043 , A61K9/0073 , A61K2039/522 , A61K2039/543 , A61K2039/58 , Y02A50/405
摘要： A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response mechanism.
摘要翻译：用于治疗或预防Th2介导的疾病或病症的药物组合物包括活的，杀死的或被注意的弗朗西斯坦弧菌或其组分。土拉木霉菌属细胞可以是LVS细胞。有效量的施用可以通过T辅助细胞（Th）1介导的抑制正在进行的Th2应答机制来预防或减少支气管收缩或过敏性气道炎症。

5. 发明授权

US08834895B2 Use of Francisella tularensis for prevention and treatment of allergic airway disorders 有权
标题翻译：使用土拉弗朗西斯菌来预防和治疗过敏性气道疾病
公开(公告)号：US08834895B2
公开(公告)日：2014-09-16
申请号：US12529678
申请日：2008-03-20
申请人： Wangxue Chen , Girishchandra Babubhai Patel
发明人： Wangxue Chen , Girishchandra Babubhai Patel
IPC分类号： A61K39/02 , A61K39/00 , A61K9/00
CPC分类号： A61K39/0208 , A61K9/0043 , A61K9/0073 , A61K2039/522 , A61K2039/543 , A61K2039/58 , Y02A50/405
摘要： A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response mechanism.
摘要翻译：用于治疗或预防Th2介导的疾病或病症的药物组合物包括活的，杀死的或被注意的弗朗西斯坦弧菌或其组分。土拉木霉菌属细胞可以是LVS细胞。有效量的施用可以通过T辅助细胞（Th）1介导的抑制正在进行的Th2应答机制来预防或减少支气管收缩或过敏性气道炎症。

6. 发明申请

US20080220028A1 ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS 审中-公开
标题翻译：用于管理动物的ARCHAEAL极乐团聚
公开(公告)号：US20080220028A1
公开(公告)日：2008-09-11
申请号：US11956653
申请日：2007-12-14
申请人： GIRISHCHANDRA B. PATEL , Wangxue Chen
发明人： GIRISHCHANDRA B. PATEL , Wangxue Chen
IPC分类号： A61K9/00 , A61K39/00 , A61K39/02
CPC分类号： A61K47/14 , A61K9/0043 , A61K9/1272 , A61K35/66 , A61K39/39 , A61K2039/541 , A61K2039/552 , A61K2039/55511 , A61K2039/57
摘要： The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions comprising an antigen and a self-adjuvanting carrier, useful for inducing antigen-specific mucosal and systemic immune responses in the host upon immunization via a mucosal route such as intranasal. The vaccine compositions comprise multivalent cations in association with a plurality of spherical archaeal polar lipid aggregates containing aqueous compartments, the AMVAD structure, formed by the interaction of archaeosomes and antigen(s) with multivalent cations such as Ca2+, wherein the AMVAD structure acts as a self-adjuvanting carrier for the antigen(s) in the vaccine composition. Certain advantageous immune responses can also be elicited with the subject compositions.
摘要翻译：本发明提供非复制组合物，以及通过经由粘膜途径（例如鼻内）施用将包含药物，生物相关分子和/或抗原的这些组合物递送至宿主的方法。本发明提供了非复制性疫苗组合物和用于在这些疫苗组合物中递送抗原的方法，所述组合物包含抗原和自动佐剂化载体，用于在通过粘膜途径进行免疫时在宿主中诱导抗原特异性粘膜和全身免疫应答如鼻内疫苗组合物包含多种阳离子，其与含有水性隔室的多个球形古细菌极性脂质聚集体相关联，AMVAD结构通过考古体和抗原与多价阳离子如Ca 2+的交互而形成 >，其中AMVAD结构用作疫苗组合物中抗原的自身佐剂载体。也可以用主题组合物引发某些有利的免疫应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式